Oxford-based AI drug pioneer Exscientia has slimmed down its drug pipeline to four candidates focusing on inflammatory disease, hematology and oncology. The move is aimed at generating data to support their potential regulatory approval. The company, anticipating at least one of its preclinical candidates will enter the clinic in 2024, is looking to emphasise its high-value, differentiated oncology targets, according to CEO Andrew Hopkins. Exscientia is also seeking partners or licensees for a dropped candidate.
Kowloon East Cluster April 05: 56k Patient Data Leak Spurs Cyber Spend – Meyka
Kowloon East Cluster April 05: 56k Patient Data Leak Spurs Cyber Spend Meyka
